Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?-Reference-Cited by-同舟云学术

Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?

Published:2013-07-18 Issue:8 Volume:28 Page:1738-1750
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Søe Kent¹,Plesner Torben²,Jakobsen Erik H³,Hansen Charlotte T⁴,Jørgensen Henrik B⁵,Delaissé Jean-Marie¹

Affiliation:

1. Department of Clinical Cell Biology; Institute of Regional Health Research, University of Southern Denmark, Vejle Hospital/Lillebaelt Hospital; Vejle; Denmark

2. Section of Hematology, Medical Department; Vejle Hospital/Lillebaelt Hospital; Vejle; Denmark

3. Department of Oncology; Vejle Hospital/Lillebaelt Hospital; Vejle; Denmark

4. Department of Hematology; Odense University Hospital; Odense; Denmark

5. Department of Nuclear Medicine; Vejle Hospital/Lillebaelt Hospital; Vejle; Denmark

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Reference50 articles.

1. Bisphosphonates: the first 40 years;Russell;Bone.,2011

2. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases;Ibrahim;Clin Cancer Res.,2003

3. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial;Black;JAMA.,2006

4. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid;Brown;Clin Cancer Res.,2007

5. Five years of anti-resorptive activity after a single dose of zoledronate: results from a randomized double-blind placebo-controlled trial;Grey;Bone.,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinicopathological characteristics and prognostic risk factors of breast cancer patients with bone metastasis;Annals of Translational Medicine;2021-08

2. Management of Myeloma Bone Lesions;International Journal of Molecular Sciences;2021-03-25

3. Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals;JBMR Plus;2020-09-29

4. Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience;Journal of Bone and Mineral Research;2016-04-19

5. Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease;Seminars in Dialysis;2015-05-05